Serum sialic acid levels in patients with oral and maxillofacial malignancy

Xing, Ruiyun; Chen, Ruimei; Wang, Zhisan; Zhang, Yuzhuo

doi:10.1016/0278-2391(91)90013-c

Cited by 13 publications

(6 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Xing et al . [26] and Bathi et al . [27] also showed elevated levels of serum sialic acid in oral cancer group as compared to the control group but did not include premalignant group.…”

Section: Discussionmentioning

confidence: 99%

Estimation of salivary sialic acid in oral premalignancy and oral squamous cell carcinoma

et al. 2016

View full text Add to dashboard Cite

Aims:Oral cancer is the most life-threatening disease of oral tissues. In societies where the incidence of oral cancer is high, clinically recognizable premalignant lesions are particularly common. Diagnosing oral cancers at an early stage is critical in improving the survival rate and reducing the morbidity associated with the disease. Alterations in the sialic acid levels in cancer patients have stimulated interest in this sugar residue as a possible tumor marker.Settings and Design:The purpose of this study was to estimate the salivary sialic acid levels in patients with oral premalignancy and squamous cell carcinoma and to correlate it with their grades to develop a cost-effective and noninvasive diagnostic parameter.Materials and Methods:Unstimulated whole saliva was collected from the groups under study and subjected to biochemical analysis for determination of sialic acid levels.Statistical Analysis Used:The salivary sialic acid levels were correlated with the clinical stage and histological grade by one-way ANOVA (SPSS software version 15).Results:Salivary sialic acid was elevated in oral squamous cell carcinoma (OSCC) compared to oral premalignancy and control group. A statistically significant correlation was observed between the grades of squamous cell carcinoma, grades of dysplasia in premalignancy, and sialic acid level.Conclusion and Clinical Significance:Evaluation of salivary sialic acid levels in premalignant and malignant lesions can serve as a screening tool. The mortality and morbidity of OSCC can be reduced if the lesions are diagnosed in early precancerous states using such noninvasive diagnostic methods for screening and monitoring of the population.

show abstract

“…Xing et al . [26] and Bathi et al . [27] also showed elevated levels of serum sialic acid in oral cancer group as compared to the control group but did not include premalignant group.…”

Section: Discussionmentioning

confidence: 99%

Estimation of salivary sialic acid in oral premalignancy and oral squamous cell carcinoma

et al. 2016

View full text Add to dashboard Cite

show abstract

“…To our knowledge, no reliable circulating tumor marker currently is available for use in the treatment of patients with oral SCC, despite efforts to establish such a marker 26–30, 37. This is a major drawback in the field because the importance of the early detection of these lesions cannot be overemphasized.…”

Section: Discussionmentioning

confidence: 99%

Early diagnosis and treatment monitoring roles of tumor markers Cyfra 21-1 and TPS in oral squamous cell carcinoma

Nagler

Barak²,

Peled

et al. 1999

Cancer

View full text Add to dashboard Cite

BACKGROUND Mucosal oral squamous cell carcinoma (SCC) accounts for 3–5% of all reported cancers, with a 5‐year survival rate of approximately 50%. Unfortunately, current detection means are of no value in diagnosing lesions early enough for cure, especially when they recur after resection. Postoperative radiotherapy and/or covering the resection site with reconstructive flaps (regional or free vascularized) often makes early diagnosis an impossible task. METHODS The authors examined the detection and treatment monitoring capacity of two relatively new tumor markers in the serum of SCC patients, comparing their levels with those in patients with other oral/perioral malignancies or benign oral tumors and with disease free, posttreatment SCC patients and healthy controls. RESULTS Values of sensitivity, specificity, and positive and negative prediction for Cyfra 21‐1 were 96%, 87%, 93%, and 53%, respectively, whereas those for tissue polypeptide specific antigen (TPS) were 69%, 87%, 93%, and 54%, respectively. Approximately 2–3 weeks after resection of the SCC lesion, Cyfra 21‐1 and TPS levels were reduced by 47% (P ≤ 0.003) and 36% (P ≤ 0.041), respectively. Cyfra 21‐1 levels in SCC patients were significantly greater than those of healthy patients by 73% (P ≤ 0.0001), patients with benign tumors by 74% (P ≤ 0.0003), and patients in disease remission by 66% (P ≤ 0.0002). Similarly, the TPS levels of SCC patients were significantly greater than those of healthy patients by 59% (P ≤ 0.0005), patients with benign tumors by 55% (P ≤ 0.0001), and patients in disease remission by 59% (P ≤ 0.0001). In two patients, a second, new SCC lesion was diagnosed within the follow‐up period, with increased tumor markers noted concomitantly with the diagnosis. CONCLUSIONS The accumulated data point to the suitability of the clinical usage of these two markers, especially Cyfra 21‐1, in the early detection of oral SCC lesions (primary, recurrent, or secondary) as well as for treatment monitoring. These results may open new avenues for the diagnosis and follow‐up of these patients and hopefully improve their treatment outcome. Cancer 1999;85:1018–25. © 1999 American Cancer Society.

show abstract

“…[8] Usefulness of serum sialic acid as a biomarker for various malignancies, including oral cancer is well established and was found to be well correlated with tumor progression or reduction in tumor mass and recurrence or metastasis in oral cancer. [6,[8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26] Saliva being a biofluid, which is a filtrate of serum from the vasculature that nourishes the salivary glands, any change that occurs in the serum as a result of disease process will be reflected in saliva. [27] However, studies in this direction particularly related to glycoconjugate components, such as sialic acid, are very few in the literature.…”

Section: Introductionmentioning

confidence: 99%

Serum and salivary sialic acid as a biomarker in oral potentially malignant disorders and oral cancer

et al. 2014

View full text Add to dashboard Cite

Background: Aberrant glycosylation is the universal feature of cancer and components of various glycoconjugates, such as sialic acid is found to rise in various malignancies. The objective of this study was to evaluate the serum and salivary sialic acid in oral potentially malignant disorders (OPMD) and oral cancer (OC) to investigate the possibility of using this as a diagnostic marker. Materials and Methods: The study included 85 subjects, who were grouped as control (30), OPMD patients (25), and oral cancer patients (30). Serum and unstimulated whole saliva was collected from subjects of all groups and sialic acid estimation was done using spectrophotometry. The results were tabulated and analyzed statistically. Results: The mean serum sialic acid levels in normal, OPMD, and oral cancer group were 7.515, 19.620, and 55.235 mg/dL, respectively, whereas the levels of salivary sialic acid were 1.5113, 2.3302, and 9.0304 mg/dL, respectively. A very highly significant rise (P < 0.005) in serum and salivary sialic acid was observed in the study subjects compared with that of the control. Conclusions: The present study showed a significant and gradual increase in serum and salivary sialic acid from control to oral potentially malignant disorders to oral cancer. From this study we can suggest that sialic acid can be used as a reliable biomarker. As this monosaccharide is observed in saliva in detectable quantity, saliva can be used as a diagnostic medium for screening and early detection of oral cancer.

show abstract

Serum sialic acid levels in patients with oral and maxillofacial malignancy

Cited by 13 publications

References 13 publications

Estimation of salivary sialic acid in oral premalignancy and oral squamous cell carcinoma

Estimation of salivary sialic acid in oral premalignancy and oral squamous cell carcinoma

Early diagnosis and treatment monitoring roles of tumor markers Cyfra 21-1 and TPS in oral squamous cell carcinoma

Serum and salivary sialic acid as a biomarker in oral potentially malignant disorders and oral cancer

Contact Info

Product

Resources

About